Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Deals
Features
News
Region
Sectors
Size
Uncategorised

Deals

Daily deal net: July 31, 2020
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Omega transcends to collect $85m
Omega Therapeutics is firing up preclinical development of an epigenomic drug platform invented at Whitehead Institute and incubated by Flagship Pioneering.
Nura Bio navigates $73m series A
Nura Bio is working on neuroprotective treatments that exploit discoveries made at OHSU and UT Southwestern.
Instrumental orchestrates $20m
Stanford-StartX Fund has backed the electronics manufacturing management software developer, with the proceeds going to product development.
Daily deal net: July 30, 2020
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Thrive prospers with $257m round
Thrive Earlier Detection, the developer of an early cancer screening blood test invented at JHU, has raised $257m in series B funding.
Sema4 sequences $121m series C
Sema4, spun out of Icahn School of Medicine, has achieved a valuation of more than $1bn following a $121m series C round.
Yissum spinouts haul in $79m in H1 2020
Funding for HUJ spinouts remained stable during the first six months of 2020 as the Israeli VC sector showed signs of resilience amid Covid-19.

News Continued

Bright Peak ascends to $35m series A
Drug protein discovery company Bright Peak hopes to deliver conjugated cancer immunotherapies based on an ETH Zürich-invented platform.
Praxis Precision works out $110m series C1
Co-founded by faculty from Columbia University and University of Melbourne, Praxis Precision Medicines targets CNS disorders.
Daily deal net: July 28, 2020
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Enthera enters $32.8m series A round
Enthera Pharmaceuticals was co-founded by faculty from University of Milan and is using stem cells to treat autoimmune disorders.
CureVac files for IPO
CureVac has filed for an initial public offering in the US, 20 years after being spun out of Eberhard Karls University of Tübingen.
MBX Biosciences extrapolates $34.6m
IU Philanthropic Venture Fund returned for a series A round expected to help MBX identify clinical-stage peptides for rare endocrine genetic diseases.

Editor's Picks

Big deal: Oxford PV begins capturing series D
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Otsuka takes up Veryan’s acquisition offer
ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.
Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
test reg

Login